Page 53 - 南京医科大学学报自然科学版
P. 53

第42卷第4期                           南京医科大学学报(自然科学版)
                  2022年4月                   Journal of Nanjing Medical University(Natural Sciences)     ·503 ·


               ·临床研究·

                LDL⁃C/HDL⁃C 对慢性髓系白血病患者深度分子学反应的预测

                价值



                徐子瑶,胡金花,孙 倩,刘文洁,洪                鸣,钱思轩     *
                南京医科大学第一附属医院血液科,江苏 南京                 210029




               [摘   要] 目的:探讨血脂水平对慢性髓系白血病慢性期(chronic myeloid leukemia⁃chronic phase,CML⁃CP)患者治疗反应的预
                测价值。方法:回顾性分析453例CML⁃CP患者的临床资料。采用全自动生化分析仪检测患者在初诊时及不同缓解阶段的血
                脂水平,应用Logistic回归模型进行预后相关因素分析。结果:CML患者与正常人相比表现为总胆固醇(total cholesterol,TC)、
                高密度脂蛋白胆固醇(high⁃density lipoprotein cholesterol,HDL⁃C)、低密度脂蛋白胆固醇(low⁃density lipoprotein cholesterol,LDL⁃C)
                水平低,甘油三酯(triglyceride,TG)、TC/HDL⁃C、non⁃HDL⁃C/HDL⁃C和TG/HDL⁃C水平高(P < 0.001),LDL⁃C/HDL⁃C无明显差异
               (P > 0.05),且不同年龄段血脂谱改变与总体趋势一致,绝经期后患者表现为TG和LDL⁃C水平高。CML患者达到主要分子学
                反应(major molecular response,MMR)及深度分子学反应(deep molecular response,DMR)时血脂水平相较于初诊时明显恢复。与
                MMR患者相比,DMR患者表现为更低水平的LDL⁃C、TC/HDL⁃C、LDL⁃C/HDL⁃C和non⁃HDL⁃C/HDL⁃C(P < 0.05)。多因素Logistic
                回归分析表明 LDL⁃C/HDL⁃C(OR=0.511,95%CI:0.330~0.793,P=0.003)、Sokal 评分(P=0.016)和酪氨酸激酶抑制剂(tyrosine
                kinase inhibitor,TKI)治疗时间(OR=1.025,95%CI:1.013~1.037,P < 0.001)与DMR显著相关。结论:初诊CML患者血脂代谢紊
                乱,TKI有效逆转血脂谱。血脂水平监测对于CML患者疗效评估具有重要意义,且LDL⁃C/HDL⁃C 可作为MMR患者预测DMR
                的独立指标。
               [关键词] 慢性髓系白血病;酪氨酸激酶抑制剂;深度分子学反应;血脂;LDL⁃C/HDL⁃C;治疗反应

               [中图分类号] R733.7                    [文献标志码] A                      [文章编号] 1007⁃4368(2022)04⁃503⁃09
                doi:10.7655/NYDXBNS20220407



                Predictive value of LDL ⁃ C/HDL ⁃ C for deep molecular response in patients with chronic
                myeloid leukemia in chronic phase

                XU Ziyao,HU Jinhua,SUN Qian,LIU Wenjie,HONG Ming,QIAN Sixuan *
                Department of Hematology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China



               [Abstract] Objective:To investigate the predictive value of lipid levels on response to therapy in patients with chronic myeloid
                leukemia in chronic phase(CML⁃CP). Methods:The clinical data of 453 patients with CML⁃CP were retrospectively analyzed. Serum
                lipid levels were compared between groups. Logistic regression models were applied to analyze prognostic ⁃related factors. Results:
                Patients with CML showed low total cholesterol(TC),high ⁃ density lipoprotein cholesterol(HDL ⁃ C),and low ⁃ density lipoprotein
                cholesterol(LDL⁃C)levels and high triglyceride(TG),TC/HDL⁃C,non⁃HDL⁃C/HDL⁃C,and TG/HDL⁃C levels compared with normal
                controls(P < 0.001),and no significant difference in LDL⁃C/HDL⁃C(P > 0.05). The changes of blood lipid profiles in different age
                groups were consistent with the overall trend,and post ⁃ menopausal patients showed high levels of TG and LDL ⁃ C. Lipid levels
                recovered significantly at the time of achieving major molecular response(MMR)and deep molecular response(DMR)compared to the
                initial diagnosis. Patients with DMR showed lower LDL ⁃C,TC/HDL⁃C,LDL⁃C/HDL⁃C,and non⁃HDL⁃C/HDL⁃C compared to
                patients with MMR(P < 0.05). Multivariate logistic regression analysis showed that LDL⁃C/HDL⁃C(OR=0.511,95%CI:0.330~
                0.793,P=0.003),Sokal risk score(P=0.016)and duration of TKI treatment(OR=1.025,95% CI:1.013~1.037,P < 0.001)were
                significantly associated with the achievement of DMR. Conclusion:Lipid metabolism is disturbed in patients with newly diagnosed


               [基金项目] 国家自然科学基金(81870119,82170153)
                ∗
                通信作者(Corresponding author),E⁃mail:qiansx@medmail.com.cn
   48   49   50   51   52   53   54   55   56   57   58